Increasing evidence points to an association between major depressive disorders (MDDs) and diverse types of GABAergic deficits. In this review, we summarize clinical and preclinical evidence supporting a central and causal role of GABAergic deficits in the etiology of depressive disorders. Studies of depressed patients indicate that MDDs are accompanied by reduced brain concentration of the inhibitory neurotransmitter c-aminobutyric acid (GABA) and by alterations in the subunit composition of the principal receptors (GABA A receptors) mediating GABAergic inhibition. In addition, there is abundant evidence that suggests that GABA has a prominent role in the brain control of stress, the most important vulnerability factor in mood disorders. Furthermore, preclinical evidence suggests that currently used antidepressant drugs (ADs) designed to alter monoaminergic transmission and nonpharmacological therapies may ultimately act to counteract GABAergic deficits. In particular, GABAergic transmission has an important role in the control of hippocampal neurogenesis and neural maturation, which are now established as cellular substrates of most if not all antidepressant therapies. Finally, comparatively modest deficits in GABAergic transmission in GABA A receptor-deficient mice are sufficient to cause behavioral, cognitive, neuroanatomical and neuroendocrine phenotypes, as well as AD response characteristics expected of an animal model of MDD. The GABAergic hypothesis of MDD suggests that alterations in GABAergic transmission represent fundamentally important aspects of the etiological sequelae of MDDs that are reversed by monoaminergic AD action.
Introduction
Major depressive disorder (MDD) represents a complex neuropsychiatric syndrome with a lifetime prevalence of B17% of the population worldwide. 1 It exhibits high comorbidity with anxiety disorders, with 50-60% of depressed patients reporting a lifetime history of anxiety disorders, and many anxiety disorder patients showing a history of treatment for depression. [2] [3] [4] [5] [6] [7] [8] [9] Antidepressant drug (AD) treatments currently in use for both anxiety and depressive disorders are designed to target monoaminergic neurotransmission, and they have set the foundation for the so-called catecholamine 10, 11 and serotonin 12, 13 hypotheses of affective disorders. Collectively, these hypotheses posit that antidepressants act by increasing the extracellular concentration and function of monoamine transmitters in the forebrain 14 and, by extension, that mood disorders are caused by altered production, release, turnover or function of monoamine transmitters or by altered function of their receptors. However, there is a growing consensus that altered monoaminergic transmission is insufficient to explain the etiology of depressive disorders 15 and that currently used antidepressants instead are modulating other neurochemical systems that have a more fundamental role in MDD. 16 A more recent hypothesis suggests that depressive disorders represent stress disorders. It is supported by a large body of epidemiological evidence showing that stress is a major vulnerability factor for mood disorders. [17] [18] [19] This evidence includes altered hypothalamic-pituitary-adrenal (HPA) axis function in patients, 20, 21 polymorphisms in the CRH1 (corticotrophin-releasing hormone 1) receptor gene that are associated with mood disorders, 22 as well as data obtained from rodents showing that central administration of stress-related hormones can produce pathologies reminiscent of MDD, which are reversed by AD treatments. 23, 24 An extension of the stress hypothesis puts forward that depressive disorders are caused by inadequate trophic support of neurons and impaired neural plasticity. [25] [26] [27] [28] However, none of the current hypotheses have identified a unified molecular framework that is broadly implicated in the etiology of mood disorders and AD mechanisms.
In this review, we summarize older but underreported and recent or emerging evidence in support of a fourth hypothesis that posits that etiological origins of mood disorders converge on genetic, epigenetic or stress-induced deficits in GABAergic transmission as a principal cause of MDDs, and that the therapeutic effects of currently used monoaminergic antidepressants involve downstream alterations in GABAergic transmission.
GABA and its receptors
GABA A receptors vs GABA B receptors g-Aminobutyric acid (GABA) is the principal neurotransmitter mediating neural inhibition in the brain. GABAergic neurons are present throughout all levels of the neuraxis, represent between 20 and 40% of all neurons depending on brain region and are known to balance and fine-tune excitatory neurotransmission of various neuronal systems, including the monoaminergic and cholinergic projections to the forebrain. GABA exerts its effects by activation of two entirely different classes of receptors: the ionotropic GABA A receptors (GABA A Rs) and the metabotropic GABA B Rs. GABA A Rs are known as key control elements of anxiety state based on the potent anxiolytic activity of benzodiazepines (BZs), which act as positive allosteric modulators of a major subset of GABA A Rs. Accumulating evidence described below points to marked alterations in GA-BA A R signaling in both anxiety and mood disorders. GABA B Rs are members of the G protein-coupled receptor (GPCR) family and they have been recently implicated in affective disorders based on altered anxiety-and depression-related behavioral measures in mice subjected to pharmacological and genetic manipulations of these receptors. GABA B (1) and GABA B (2)R knockout (KO) mice show behavior that is indicative of increased anxiety combined with an antidepressant phenotype. 29, 30 Consistent with these genetic studies, positive GABA B R modulators show potential as anxiolytics, whereas antagonists have antidepressant-like effects in animal experiments. 29 However, given the strong evidence for comorbidity of anxiety and depressive disorders, opposing actions of GABA B -directed ligands on anxiety-and depression-related measures are likely to limit the potential of GABA B R-directed therapeutic approaches. Therefore, in this review, we will focus on GABA signaling through GABA A Rs, the receptors that mediate the vast majority of GABA function.
Structure of GABA A Rs

Subunit composition
Structurally, GABA A Rs represent heteropentameric GABA-gated chloride channels that are assembled from subunits encoded by 19 different genes (namely a1-6, b1-3, g1-3, d, e, y, p and r1-3). Different combinations of these subunits give rise to a large number of structurally, functionally and pharmacologically distinct receptor subtypes, of which B25 have been either definitely or tentatively identified. 31 These can be roughly subdivided into (1) postsynaptic and (2) extrasynaptic or perisynaptic subtypes, although some neurons also contain GABA A Rs at axon terminals. The postsynaptic GABA A R subtypes mainly include a1bg2, a2bg2 and a3bg2 receptors the b-subunits of which remain ill defined; they tend to be concentrated at synapses where they mediate phasic inhibitory synaptic currents in response to synaptically released GABA. The latter consists of a4bd and a5bg2 receptors in the forebrain and of a6bd receptors in the cerebellum. They are located on somatodendritic membrane compartments away from the synaptic cleft and are tonically activated by low ambient concentrations of GABA or GABA spilled over from synapses. 31, 32 Functional dissociation of different subtypes of BZ-sensitive GABA A Rs Benzodiazepines act as positive allosteric modulators of GABA A Rs composed of a1bg2, a2bg2, a3bg2 or a5bg2 subunits. Using a combined molecular genetic and behavioral pharmacological strategy, these GA-BA A R subtypes were assigned to different diazepamsensitive behaviors based on the specific type of asubunits present. 33, 34 In particular, it was found that the broadly expressed a1bg2 receptor subtype mediates sedative, anterograde amnesic, addictive and most of the anticonvulsant effects of diazepam. [35] [36] [37] [38] In contrast, a2bg2 receptors control the anxiolytic and anti-hyperalgesic properties, 39, 40 and a2bg2, a3bg2 and a5bg2 receptors together mediate the myorelaxant effects of diazepam. 41, 42 a5bg2 receptors are further important for normal hippocampus-dependent associative memory functions and for the development of tolerance to the sedative functions of diazepam. [42] [43] [44] [45] The prevalent distribution of a2bg2 receptors in the cerebral cortex, hippocampus and amygdala 46 and the role of this receptor subtype in anxiolysis is consistent with the established role of corticolimbic brain regions in the control of emotional states. 47, 48 Moreover, the identification of a1bg2 receptors in interneurons of the ventral tegmental area as substrates for the addictive properties of BZs 37 suggests that functional deficits of these receptors may contribute to anhedonia as seen in GABA A R g2 subunit-deficient mice 49 (see below). Functional deficits in a1bg2 receptors can be predicted to increase GABA release by ventral tegmental area interneurons and to enhance GABAergic inhibition of the nearby dopaminergic neurons, and thereby to contribute to anhedonia as a core symptom of MDD.
BZ-insensitive GABA A Rs
In contrast to most postsynaptic g2-containing GABA A Rs, the extrasynaptic receptor subtypes composed of a4bd subunits in the forebrain and of a6bd subunits in the cerebellum are insensitive to the GABA-potentiating effects of BZs, and they conduct a prominent tonic form of inhibition. Nevertheless, they exhibit a high affinity for the imidazo-BZ Ro15-4513 and flumazenil, as well as for the iodinated flumazenil derivative [ 123 I]iomazenil. [50] [51] [52] Therefore, these receptors are included along with BZ-sensitive GABA A Rs in autoradiographic and nuclear tomographic measurements using these ligands. a4bd receptors are of increasing interest as they are dynamically regulated by stress and other hormonal stimuli implicated in mood disorders.
Brain imaging studies suggest a role for altered GABAergic transmission in anxiety and depressive disorders
GABA deficits in depression
The strongest evidence that GABAergic deficits may contribute to depressive disorders is based on reduced GABA levels in plasma 53, 54 and cerebrospinal fluid 55 or in resected cortical tissue 56 of depressed patients. Although the initial findings were controversial 57 or lacked statistical significance, 58 the more recent assessments of GABA deficits in the brain using proton magnetic resonance spectroscopy show dramatic reductions of GABA in the occipital cortex 59, 60 and lower but still significant reductions in the anterior cingulate and dorsomedial/dorsolateral prefrontal cortex 61, 62 of MDD patients. This neurochemical phenotype is consistent with a selective loss of calbindin-positive GABAergic interneurons observed in the dorsal prefrontal cortex of depressed patients. 63 Interestingly, GABA deficits are most pronounced in melancholic and treatment-resistant subtypes of depression (À50%), 56, 60, 64 whereas reductions in depressed patients who do not meet the criteria of melancholia, 60 and in bipolar patients 65 are less severe (À20%).
GABA A R deficits in anxiety disorders
Reduced abundance of GABA A R-binding sites suggests a role for GABAergic deficits in anxiety disorders. Positron emission tomography scanning using the BZ site antagonist 11 C-flumazenil shows global reductions in GABA A R-binding sites in patients suffering from panic attacks, with the most robust changes in the ventral basal ganglia, orbitofrontal and temporal cortices, 66 which are believed to control the experience of anxiety. 67, 68 Moreover, although flumazenil has no behavioral effect in healthy people, it precipitates panic attacks during symptom-free episodes in panic patients, suggesting unusual inverse agonist properties. 69 Analyses by single photon emission computed tomography with a similar ligand ([ 123 I]iomazenil) show widespread reductions in GABA A R-binding sites in the superior frontal, temporal and parietal cortices, 70 the left hippocampus and precuneus 71 of panic patients. Similar analyses have revealed GABA A R deficits in the temporal lobe of patients with generalized anxiety disorder 72 and in the medial prefrontal cortex of patients suffering from posttraumatic stress disorder. 73 Collectively, these data suggest that different anxiety disorders involve GABA A R deficits in different brain regions.
Gene expression changes associated with MDD suggest altered expression and subunit composition of GABA A Rs In contrast to anxiety disorders, the density of GABA A R [ 123 I]iomazenil-binding sites in the brain of depressed subjects is largely unchanged. 74 A notable exception is a single patient suffering from severe treatment-resistant anxious depression with panic attacks linked to a silent point mutation in the GABA A R b1-subunit gene. 75 However, there is abundant evidence for a role of GABA A Rs in major depression based on altered expression of GABA A R subunit transcripts (Table 1) . A genome-wide screen for changes in transcript levels in the frontopolar cortex (Brodmann area 10) of suicide victims who had suffered from various forms of depressive disorders has revealed reductions in the abundance of a1, a3, a4 and d subunit mRNAs. 76 Evidence for similarly discoordinated expressions of GABA A R subunit transcripts is also available for other brain areas implicated in mood disorders. 82 These studies did not differentiate among changes linked to depression, suicide or suicide-associated distress, and thus need to be confirmed in a more representative cohort of patients and controls. Interestingly, the reduced expression of the a1 mRNA was associated with increased DNA methylation of transcriptional control regions of the GABRA1 gene and with the upregulated expression of the DNA methyltransferase DNMT-3B, suggesting that GABRA1 gene expression is subject to epigenetic control. 83 A comparison of postmortem brains of depressed vs nondepressed suicide victims has revealed increased expression of a5, g2 and d subunit mRNAs in the dorsolateral prefrontal cortex (Brodmann area 44/46) . 80 This is consistent with an earlier report showing upregulation of b3, g2 and d subunit mRNAs in nearby brain regions (Brodmann area 9, 46) of depressed patients who died from more diverse causes. 79 This latter study has further identified selective upregulation of a5 mRNA in the anterior cingulate cortex (Brodmann area 24), a critical component of the corticolimbic pathway affected in major depression. 84 A comprehensive screen for gene expression changes in 17 cortical and subcortical brain regions from depression-related suicides found that genes that are involved in GABAergic transmission are among the most consistently changed. 77 Among a total of 27 GABAergic probe sets differentially expressed in the frontal cortex or hippocampus, no fewer than 19 involve genes that encode GABA A R subunits. GABA A R subunit genes are mostly upregulated in depression-related suicides, perhaps as a compensatory mechanism for low GABA levels associated with depression. Low levels of GABA A R gene expression among suicides that lack a history of depression suggest that elevated expression in depression-related suicides may in fact be depression specific. 77 These increases in GABA A R subunit mRNAs seem to contradict the aforementioned unaltered levels of GABA A R-binding sites 74 in suicide brains. However, altered subunit mRNA levels do not necessarily have to result in changes in GABA A Rbinding sites, neither of which are representative of functional receptors present at the plasma membrane or at synapses. Discoordinated expression of GABA A R subunits might give rise to functionally distinct GABA A R subtypes that nevertheless bind [
123 I]iomazenil. Finally, GABA A Rs are subject to phosphorylation, palmitoylation and ubiquitination, all of which regulate the cell surface expression and accumulation of GABA A Rs at synapses, as well as inhibitory synaptogenesis. 85, 86 These posttranslational modifications allow for modulation of GABA A R cell surface expression by environmental and physiological cues implicated in mood disorders. Accordingly, mutations in trafficking proteins that regulate the portion of GABA A Rs at synapses affect anxiety and moodrelated behavior in both patients 87 and animal models. 88, 89 Genetic evidence in support of GABAergic deficits in mood disorders
There is growing evidence that suggests that genetic polymorphisms in GABA A R subunit genes are involved in affective disorders. The Wellcome Trust Case Control Consortium 90 has identified a strong association between bipolar disorder and polymorphism in the GABRB1 gene coding for the b1 subunit of GABA A Rs. A follow-up study has confirmed this finding and has extended it to associations with nucleotide polymorphisms in GABRA4, GABRB3, GABRA5 and GABRR3 subunit genes. 91 Notably, GABRB1 and GABRA4 are part of the same gene cluster on chromosome 4p12, together with GABRA2, whereas GABRA5 and GABRB3 are part of a cluster at 15q11-q13, which had previously been implicated in bipolar disorder. 92 Associations between nucleotide polymorphisms and bipolar disorder further exist for 
GABRA3
93 and GABRB2, 94 with the latter implicated in alternative splicing of the b2 subunit mRNA. 95 For MDD, genetic associations have been described for GABRA5 96 and the gene cluster encoding GABRA1, 97, 98 GABRA6 and GABRG2. 98 Although not all studies have found this latter association, 99 this same gene cluster is also linked to depression-related behavior in mice. 100 Finally, there is recent evidence for a male-specific association between noncoding genetic polymorphisms of the GABRD gene and childhood-onset mood disorders. 101 In summary, the data suggest that GABAergic deficits can lead to mood disorders but also demonstrate that genetic polymorphisms at the level of GABA A R subunit genes account for at most a small percentage of mood disorders, and that environmental and remote genetic triggers of GABAergic deficits may be more important.
Modulation of GABA A Rs by stress: a major risk factor of depressive disorders Effects of early life stress Stress represents the most important vulnerability factor for MDD and related neuropsychiatric disorders, both in the developing [102] [103] [104] [105] [106] and in the adult nervous system. 107 There is a growing body of preclinical evidence that suggests that much of this vulnerability may be due to stress-induced impairment of GABAergic transmission. For example, maternal separation stress of rats during the initial postnatal weeks leads to increased neophobia and acoustic startle responses in adulthood, and this phenotype is associated with reduced expression of BZ-sensitive GABA A Rs in the frontal cortex, amygdala, locus coeruleus and the nucleus tractus solitarius. 108 The level of maternal care measured in the form of pup licking in rodents is positively correlated with GABA A R mRNA expression and is inversely related to behavioral stress reactivity in adulthood. 109 Analyses of GABA A R g2-deficient mice 49, 110 (further discussed below) suggest that modest reductions in GABA A R function during development are not just correlated with anxiety-and depression-related behavior in adulthood, but that they can be causal.
Effects of stress in adulthood
In addition to early life stress effects on GABA A R expression in the mature brain, there is extensive literature on stress-induced changes in the expression and function of GABA A Rs in the adult brain. The exact consequences of acute stress on GABA A R expression in rodents seem to depend on the type of stress protocol, sex and brain region(s) analyzed. 111 More relevant in the context of this review, however, are unpredictable chronic forms of stress that are suitable to model depressive-like symptoms in animal models. 112, 113 The prevalent effect of chronic stress in the cerebral cortex is reduced abundance and function of GABA A Rs. 114 By contrast, the effects of chronic stress hormone exposure in the hippocampus are uneven, as well as subunit and layer specific. 115, 116 In particular, the expression of a4bd receptors is subject to prominent chronic stress-induced augmentation in granule and pyramidal cell neurons of the hippocampus. 117, 118 This chronic effect is believed to alter the sensitivity of the brain to acute stressassociated increases in neuroactive steroids, as discussed further below.
GABAergic control of the HPA axis Increased secretion of glucocorticoids and aberrant function of the HPA axis are well-replicated findings in a major subset of patients suffering from severe forms of depressive disorders, especially melancholic depression 19, 21, [119] [120] [121] [122] ( Figure 1 ). The paraventricular nucleus (PVN) of the hypothalamus, which is the source of CRH that dictates HPA axis responses to stress [131] [132] [133] is subject to GABAergic inhibitory control by the frontal cortex 132, 134 and ventral hippocampus. 135 They are activated along with the PVN in response to acute emotional stress 136 and represent major sites of vulnerability to stress. 125, [137] [138] [139] In contrast to acute stress, which enhances GABAergic synaptic transmission in the ventral hippocampus, 125 chronic stress causes reductions in GABAergic synaptic currents due to the selective loss of hippocampal parvalbumin-positive interneurons. 124 This effect has been attributed to glucocorticoids acting on a membrane-bound, ill-defined receptor that evokes nitric oxide release from hippocampal pyramidal cells. 124 Even modest chronic deficits in GABAergic transmission in GABA A R g2 þ /À mice impair the survival of adult-born hippocampal neurons, 110 an effect that may explain hippocampal volume reductions observed in chronically depressed patients [140] [141] [142] (also see below). Blocking hippocampal neurogenesis in turn is sufficient to increase HPA axis activity. 126 Thus, projections from the ventral hippocampus through the lateral septum 138, 143 to the hypothalamus link hippocampal neuropathology to hyperactivity of the HPA axis and aberrant stress reactivity, which may sustain or even amplify hippocampal neuropathology.
Similar to the hippocampus, the dorsomedial and dorsolateral prefrontal cortices and the anterior and subgenual cingulate cortices represent substrates of stress-related psychiatric illness associated with cognitive and affective symptoms of MDD. 84, 139, [144] [145] [146] The deficits in cortical GABA concentrations 61, 62 and the altered expression of GABA A R subunit genes (Table 1) indicate that this phenotype involves reduced GABAergic function. In addition, cortical GABAergic inhibition is impaired by stress-induced signaling pathways, as indicated by drastic CRHinduced, serotonin-mediated desensitization of GABAergic inhibitory synaptic currents recorded from cortical slices. 147 Tracing experiments show that GABAergic neurons of the anterior bed nucleus of the stria terminalis serve to relay inhibitory control by the medial prefrontal cortex to the PVN. 123, [148] [149] [150] Moreover, mice with genetically induced cortex/ hippocampus-restricted GABA A R deficits exhibit chronically elevated HPA axis activity. 49 Thus, local cortical deficits in GABAergic inhibition and correspondingly increased neural excitability lead to increased activity of the PVN, even if the initially causal deficit is limited to extrahypothalamic circuits (also see below).
In addition to remote inhibition of the hypothalamus by cortical and hippocampal GABAergic circuits, CRH-producing neurons of the PVN themselves are subject to local GABAergic inhibitory control that is regulated by stress. 151 Chronic mild stress of rats results in a marked reduction in the frequency but unaltered amplitude of GABAergic inhibitory synaptic currents recorded from PVN neurons, suggesting presynaptic deficits in GABA release. 152 However, the postsynaptic GABAergic function of PVN neurons is also impaired, as indicated by stress-induced downregulation of the K þ -Cl À cotransporter KCC2. The ensuing depolarizing shift of the chloride-reversal membrane potential renders GABA inputs ineffective, thereby leading to increased excitability of PVN neurons. 127 Increased CRH release by PVN neurons leads to increased release of the adrenocorticotropic hormone by the anterior pituitary gland and systemically elevated basal cortisol levels (corticosterone in rodents) and other stress hormones, which are wellreplicated findings in prominent subsets of patients suffering from severe forms of depressive disorders 19, [119] [120] [121] [122] 153 ( Figure 1 ).
GABA A R modulation by neurosteroids
Stress is known to affect GABAergic inhibition at least in part through stress-induced release of endogenous neuroactive steroids that act as allosteric modulators of GABA A Rs. In particular, 3a,5a-tetrahydroprogesterone (THP, also known as [allo]-pregnanolone) and 3a,21-dihydroxy-5a-pregnan-20-one (THDOC, [allo]tetrahydrodeoxycorticosterone) are rapidly induced (4-20-fold) by stress 154 and are known to act as high-affinity modulators of extrasynaptic a4bd GABA A Rs. [155] [156] [157] THP either increases (in dentate gyrus granule cells) or reduces (in CA1 pyramidal cells) a4bd receptor-mediated tonic GABAergic inhibition, due to cell type-specific differences in chloride homeostasis and steroid-induced receptor desensitization, which depends on the direction of the chloride gradient. 157, 130 Preclinical and clinical data indicate that plasma concentrations of THP and THDOC are reduced and increased, respectively, in depressed patients [158] [159] [160] [161] and normalized by certain ADs (see below), which points to a role for neurosteroid synthesis in the pathology of depressive disorders. Although THP is an endogenous metabolite of ovarian/adrenal progesterone and also produced in the brain, THDOC is derived exclusively from adrenal sources. 154, 162, 163 Normally, a4bd receptors are readily detectable only in dentate gyrus granule cells, neurons of the thalamus, striatum and pons, and in the outer layers of the cerebral cortex. 164 However, prominent tonic inhibitory currents with a pharmacological profile of d-containing GABA A Rs in PVN neurons 165 and attenuation of adrenocorticotropic hormone and corticosterone release by THP and THDOC, 166, 167 indicate that a4bd Figure 1 HPA axis hyperactivation by frontocortical and hippocampal deficits in GABAergic inhibition. The GABAergic deficit hypothesis of MDD presented here suggests that local GABAergic deficits in the hippocampus and frontal cortex due to reduced GABA release, uncoordinated GABA A R subunit gene expression or anomalous signaling mechanisms that affect GABA A R accumulation at the plasma membrane lead to local hyperexcitability, which is relayed by projections (in the case of the frontal cortex through the BNST 123 ) to the PVN of the hypothalamus. In the hippocampus, such local GABAergic deficits may involve the loss of parvalbumin-positive interneurons, 124 reduced GABAergic synaptic inhibition 125 and reduced maturation and survival of adult-born granule cells, 110 which is sufficient to activate the HPA axis. 126 Cortical deficits in GABAergic inhibition include reduced GABA levels in patients. 61, 62 In addition, GABAergic deficits may be induced by chronic stress, which downregulates the expression and function of GABA A Rs in the frontal cortex. 114 Hyperexcitability of the cortex and hippocampus is relayed by projections to the PVN. Local GABAergic inhibition of PVN neurons may be independently compromised by a stress-induced shift in the neural Cl À -reversal potential. 127 The ensuing excessive release of CRH from the PVN results in increased release of ACTH from the anterior pituitary, which promotes the release of glucocorticoids, thereby closing a positive feedback loop that amplifies cortical and hippocampal GABAergic deficits. Adrenal neurosteroids normally potentiate GABA-mediated activation of GABA A Rs on dentate gyrus granule cells. 128, 129 Moreover, THDOC upregulates the expression of a4bd receptors in hippocampal granule cells. 117 However, in CA1 pyramidal cells of the hippocampus, the same neurosteroids facilitate GABA-induced desensitization of a4bd receptors, 130 which increases neural excitability. 128 ACTH, adrenocorticotropic hormone; BNST, bed nucleus of the stria terminalis; CRH, corticotrophin-releasing hormone; GABA, g-aminobutyric acid; HPA, hypothalamic-pituitaryadrenal; MDD, major depressive disorder; PVN, paraventricular nucleus; THDOC, 3a,21-dihydroxy-5a-pregnan-20-one.
receptors also contribute to the inhibitory control of HPA axis activity in the PVN.
The expression of a4bd receptors is dynamically regulated In CA1 pyramidal cells, the accumulation of these receptors is strongly induced on progesterone withdrawal, [168] [169] [170] at puberty 128, 171 and during pregnancy. 170 In dentate granule cells, the abundance of a4bd receptors is subject to dynamic fluctuations across the ovarian cycle, 172 during pregnancy, 170, 173, 174 and induced by stress. 117 Thus, an aberrant homeostatic regulation of neurosteroid synthesis together with cell type-specific effects on expression and function of a4bd receptors is implicated in the etiology of stress-associated mood disorders, premenstrual dysphoric disorder and postpartum depression 155, 156, 175, 176 (see below).
Pharmacological evidence in support of a role of GABAergic transmission in depressive disorders
Antidepressant efficacy of BZs A possible role of GABA A R dysregulation in mood disorders has been controversial in part because of the lack of a consensus about whether BZs are therapeutically effective for the treatment of depression. 61 However, the limited use or efficacy of BZs in AD therapies should not be taken as evidence that GABAergic deficits are not involved in the etiology of MDD. Early studies have concluded that standard tricyclic antidepressants (TCAs) are overwhelmingly superior to BZs, although the two classes of drugs were initially prescribed for depression almost interchangeably. 177 Indeed, some early studies have reported antidepressant efficacy of BZs that was comparable with that of standard antidepressants [178] [179] [180] with some studies reporting more rapid therapeutic onset 181, 182 or greater efficacy of BZs. 183 More recent meta-analyses of clinical data have concluded that the antidepressant efficacy of BZs is limited to the triazolo-BZ alprazolam, with classical BZs being ineffective beyond their established role as anxiolytics. 184, 185 Alprazolam has been rated as equivalent or superior to TCAs with respect to anxiety and sleep indices of depression, equivalent with respect to improving anergia, psychomotor retardation and anhedonia, but inferior in relieving depressed mood. 184, 185 The most obvious limitations to therapeutic efficacy of BZs are due to the rapid development of tolerance, the high risk for developing dependence, the moderate abuse potential and ultimately the danger of withdrawal symptoms. 186, 187 At the cellular level, BZs may limit the proliferation of progenitors of adult-born hippocampal neurons, which would limit the effect these drugs can have on immature neurons, which act as a substrate of AD action (see below). Nevertheless, BZs are often used in combination with standard antidepressants, even today, both for initial treatment and maintenance therapy, 188, 189 which suggests beneficial effects. Encouragingly, the sedative hypnotic agent eszopiclone, which acts as a positive allosteric agonist similar to BZs but selectively on a2bg2 and a3bg2 subtypes of GABA A Rs, shows significant promise as an antidepressant in patients suffering from depression and insomnia. [190] [191] [192] GABAergic mechanisms of monoaminergic antidepressants With the exception of some BZs mentioned above, currently used antidepressants exclusively target monoamine transmitters. They are designed to block the reuptake of extracellular serotonin (selective serotonin reuptake inhibitors, SSRIs), norepinephrine or, to a lesser extent, dopamine, or they unspecifically inhibit the intracellular degradation of monoamine transmitters. AD-induced increases in extracellular monoamines are believed to result in slow neurochemical, transcriptional, translational, posttranslational and epigenetic adaptations that underlie therapeutically effective neural plasticity. 28 However, the receptors that mediate the functionally relevant neural adaptations of drug-induced increases in monoamine transmitters and their cellular localization have not been determined conclusively. Indeed, there is evidence that antidepressants may activate G-protein signaling independently of increased monoamine transmitters. 193, 194 Even so, the antidepressant effects of serotonin in the forebrain are considered to involve 5-hydroxytryptamine-1A receptor (5-HT1AR)-mediated hyperpolarization of pyramidal cells 195 and 5-HT1B/5-HT2/5-HT3/5-HT4R-mediated excitation of GABAergic interneurons. [196] [197] [198] [199] [200] In support of this conclusion, the 5-HTR trafficking factor P11/S100A10 interacts with and regulates the cell surface expression and function of 5-HT1B 201 and 5-HT4Rs. 202 Electroconvulsive therapy (ECT) and chronic treatment with imipramine result in the upregulation of P11 mRNA and protein selectively in the forebrain. 201 Moreover, P11 is required for normal antidepressant and neurogenic effects of fluoxetine. 200 Importantly, P11 is selectively expressed in several classes of hippocampal GABAergic interneurons but absent in granule cell precursors. 200 Thus, the effects of fluoxetine, imipramine and ECT may have in common that they involve increased excitability of GABAergic interneurons, which, in turn, can be predicted to increase GABAergic activation of hippocampal granule cell precursors. 203, 204 Whereas GABAergic input to mature neurons is mostly hyperpolarizing, the depolarizing action of GABA on immature granule cells is implicated in the mechanism of monoaminergic AD action (see below).
Antidepressant drug-induced potentiation of GABA release as a mechanism underlying AD effects is congruent with chronic SSRI-mediated increases in cortical GABA concentrations observed in patients 205 and healthy volunteers. 206 However, these reports seem at odds with fluoxetine effects on GABA signaling in the visual cortex of rats. 207 Chronic fluoxetine-induced reductions in cortical GABA concentrations and correspondingly reduced GABAergic inhibition have been shown to reactivate ocular dominance plasticity in the adult brain and to promote the recovery of visual functions in adult amblyopic animals. 207 It remains to be seen whether such effects can be replicated with other antidepressants and also whether they extend to brain areas implicated in mood disorders.
Similar to SSRIs, TCAs that increase the extracellular concentration of noradrenalin and 5-HT are likely to act in part by modulating GABAergic transmission. Noradrenergic innervation of GABAergic interneurons increases GABAergic transmission in diverse forebrain regions as shown for the frontal, 208 sensorimotor 209 and entorhinal cortices, 210 the CA1 hippocampus 211 and the basolateral amygdala. 212 The selective norepinephrine reuptake inhibitor reboxetine exerts complex brain region-specific effects on the expression of interneuronal glutamic acid decarboxylase 67, the principal enzyme involved in the synthesis of GABA. 213 Immunostaining for glutamic acid decarboxylase 67 in the brain of medication-free depressed suicide victims is significantly reduced, whereas the brain of a different cohort of depressed suicide victims who had been treated with SSRIs or TCAs showed normal levels of glutamic acid decarboxylase 67. 214 Collectively, the data suggest that norepinephrine and serotonin reuptake inhibitors have in common that they potentiate GABAergic transmission.
Direct effects of ADs on GABA A Rs
In addition to their principal effects on monoamine transporters and receptors, many if not all, antidepressants can directly act on other targets that contribute to therapeutic efficacy, undesirable side effects or toxicity on overdose. For example, fluoxetine (1-10 mM) has direct off-target effects on nicotinic acetylcholine 215 [221] [222] [223] [224] [225] [226] Importantly, therapeutically relevant concentrations of fluoxetine and its metabolite norfluoxetine act as potent positive allosteric modulators of GABA A Rs in vitro when tested on receptors expressed in heterologous cells 227 and in cultured neurons. 228 This effect may not only contribute to antidepressant efficacy but also explain the unique anticonvulsant properties of fluoxetine in patients. 229 AD-induced potentiation of GABAergic transmission by neurosteroids Low concentrations of chronically applied fluoxetine or its active metabolite norfluoxetine and their relatives (such as paroxetine, fluvoxamine, sertraline) have been shown to increase plasma or cerebrospinal fluid concentrations of THP. [159] [160] [161] [230] [231] [232] [233] This effect is observed at concentrations 50 times lower than the concentration that affects 5-HT uptake. Thus, THP seems to contribute to the anxiolytic function of SSRIs. 234 The behavioral effects of THP are independent of an increase in serotonin but are attenuated by bicucullin, 235 which shows that they involve potentiation of GABA A Rs. In vitro experiments with fluoxetine, sertraline and paroxetine suggest that SSRI-induced increases in THP are due to direct drug effects on enzymes involved in THP synthesis. 236 Hippocampal administration of THP in rats has anxiolytic and antidepressant-like behavioral effects and is associated with increased expression of the g2 subunit mRNA of GABA A Rs. 237 In addition to genomic effects, THP acts as a potent positive allosteric modulator of mainly a1/4/6bd subtypes of GA-BA A Rs. 130, [238] [239] [240] [241] [242] These extrasynaptic GABA A Rs are of increasing interest in the context of mood disorders as they are subject to dynamic genomic and hormonal regulation during puberty, 128 The CSF and plasma concentrations of THP are reduced compared with normal controls in drug-free depressed patients [158] [159] [160] [161] by social isolation stress in rats, 244 and in the olfactory bulbectomy model of depression of rats. 232 Moreover, SSRIs normalize THP deficits in patients [158] [159] [160] and in bulbectomized rats. 155, 232, 245, 246 Plasma levels of THP are also elevated following partial sleep deprivation, 247 which has antidepressant effects. 248 In contrast to THP, plasma concentrations of THDOC are increased in patients and reduced by fluoxetine. 161 Unlike SSRIs or sleep deprivation, the TCA imipramine, 230, 236 repetitive transcranial magnetic stimulation 249 and ECT 250 do not affect THP plasma concentrations, suggesting that THP is not universally involved in antidepressant mechanisms. However, these THP measurements have yet to be repeated in the brain to be conclusive.
In addition to drug therapies, cognitive behavioral therapy 251 and ECT 252 ameliorate cortical GABA deficits in patients. ECT is believed to further enhance GABAergic transmission through an increase in the cortical expression of GABA A Rs. 253 Finally, noradrenergic and serotonergic neurons in the locus coeruleus and raphe nucleus, respectively, are subjected to GABAergic control. 254, 255 In particular, reduced GABAergic inhibition of serotonergic neurons is a developmental risk factor for anxiety and mood disorders, as evidenced by anxiety-and depressionrelated behavior of mice in which the serotonin transporter was inactivated either genetically (KO mice) [256] [257] [258] or pharmacologically 259 in early life. The collective information on the mechanisms of different antidepressant therapies and their effects on GABA release, neurosteroids synthesis and GABA A R expression and function indicate that enhancing GABAergic transmission lies at the core of both pharmacological and nonpharmacological antidepressant therapies.
GABAergic control of neurogenesis, a target of AD treatment
Mechanisms that regulate the production, maturation and survival of adult-born granule cells in the hippocampus (dentate gyrus) have become a focus of research on mood disorders as it was shown in rodents that these processes are enhanced by ADs [260] [261] [262] [263] and are required for many of the ADinduced behavioral responses. 262, [264] [265] [266] [267] [268] [269] Conversely, deficits in neurogenesis are a hallmark of genetic and stress-induced animal models of depression 110, 141, [270] [271] [272] and are believed to underlie hippocampal atrophy observed in chronically depressed patients. 24, 26, 27, 107, 146, [273] [274] [275] [276] [277] [278] [279] [280] The production of adultborn granule cells is unaffected by serotonin depletion. 281, 282 Moreover, noradrenaline is dispensable for normal maturation of these neurons, although it is required for normal proliferation of neural precursor cells. 281, 283 Finally, we are unaware of any conclusive evidence that monoamine transmitter receptors are expressed on replicating neural progenitors or on immature neurons. The collective evidence suggests that deficits in monoaminergic neurotransmitter systems are unlikely to represent principal culprits of anxiety-and depression-related deficits in hippocampal neurogenesis. By contrast, GABAergic signaling through GABA A Rs has emerged as an essential mechanism that controls proliferation, maturation and survival not only of adult-born neurons in the hippocampus 203, 204 but also of analogous processes in the postnatal subventricular zone of rodents that replenishes interneurons of the olfactory bulb 284, 285 and for embryonic neural progenitors that give rise to neurons of the neocortex 286 (for review, see Lledo et al. 287 and Ge et al. 288 ).
GABAergic mechanisms that control adult hippocampal neurogenesis GABA A Rs mainly have hyperpolarizing effects on the membrane potential of mature neurons. By contrast, GABA-mediated activation of GABA A Rs is depolarizing and excitatory in proliferating neural progenitors and immature postmitotic neurons 284, 286, [288] [289] [290] [291] ( Figure 2 ). The transition from GABA A R-mediated depolarization to hyperpolarization during the maturation of neurons is triggered by a developmental switch in gene expression of the two Cl À transporters NKCC1 and KCC2, which leads to a gradual shift in the membrane-reversal potential of chloride to more negative values. The negative shift of the Cl À -reversal potential in turn changes the direction of GABA A Rmediated currents from depolarizing (inward) in neural progenitors and immature neurons to mostly hyperpolarizing (outward) in mature neurons. Importantly, this switch is essential for normal structural and functional maturation and network integration of adult-born granule cells. 204 Short-term enhancement of the GABA A R function with barbiturates accelerates the differentiation of proliferating neural progenitor cells, and thereby depletes the pool of dividing cells that represents the source of adult-born neurons. 203, 284 In agreement with the negative effects of GABAergic inputs on proliferation of new hippocampal neurons, coadministration of fluoxetine with the BZ diazepam negates the effect on proliferation observed with fluoxetine alone. 292 In addition to these effects on proliferating progenitors, GABA-mediated excitation of postmitotic immature neurons results in the activation of low-threshold T-type Ca 2 þ channels, 293 higher-threshold L-type Ca, 2 þ channels [294] [295] [296] [297] and Nmethyl-D-aspartate receptors. 298 The ensuing increase in intracellular Ca 2 þ results in the activation of diverse kinases 299 (such as CaMKII (calmodulindependent protein kinase II), protein kinase C, protein kinase A), all of which can phosphorylate Ser133 of the DNA-binding transcription factor CREB (cAMP response element-binding protein) and promote the dendritic maturation and survival of these neurons 261,300-302 ( Figure 2 ).
CREB mediates GABAergic control of antidepressantinduced neurogenesis
CREB has a well-established role in learning-and memory-related synaptic plasticity 303 and is involved in hippocampus-mediated AD responses 27, 304, 305 and in the production, maturation and survival of adultborn hippocampal neurons. 261, 300, 302 Consistent with a role of CREB in MDD, CREB expression is downregulated in brain of depressed (but not schizophrenic) patients studied at the time of autopsy and increased as part of the AD response. 306 All evidence suggests that the effects of ADs on CREB activation and maturation and survival of hippocampal neurons are indirect and downstream of increased GABA signaling through GABA A Rs 302 ( Figure 1 ). Concurrent activation of CREB and increased hippocampal neurogenesis are hallmarks of all currently used antidepressants, 260, 307 suggesting that their mechanisms of action involve enhancement of GABAergic input to immature granule cells.
Among the transcriptional target genes of CREB, the brain-derived neurotrophic factor (BDNF) is of special interest. [308] [309] [310] BDNF is reduced in the serum of depressed 311, 312 and bipolar patients 313, 314 and in the dentate gyrus of chronically stressed rats. 315 Conversely, BDNF is induced on chronic treatment with diverse classes of ADs in the hippocampus of rats 316, 317 and patients, 318 and it is effective as an antidepressant on central administration in rodents. [319] [320] [321] [322] BDNF and its receptor TrkB are essential for normal anxiety-related behavior and for AD behavioral effects in mice, 267, 323, 324 as well as for normal neural maturation of hippocampal granule cells. 325 Importantly, BDNF is not only a target downstream of excitatory GABAergic transmission but through activation of TrkB receptors on GABA ergic terminals also serves to promote GABA release 326, 327 ( Figure 2 ). Thus, BDNF enables a positive feedback loop that upregulates GABAergic signaling, which explains its essential role for normal neural maturation. A related BDNF-and GABA-mediated mechanism protects mature neurons from posttraumatic injury. 328 Currently used AD therapies 317 and ECT all enhance the expression of BDNF, 316 suggesting that these therapies might include enhancement of GABAergic transmission. However, the positive feedback relationship between GABA A R activation, BDNF expression and GABA release may be selflimited to immature neurons (and possibly to other neurons with high-intracellular Cl À concentrations) as BDNF also promotes the expression of KCC2, which diminishes and eventually eliminates GABAergic depolarization. 329, 330 Indeed, in contrast to the chronic effects of BDNF in immature neurons, the acute effects of BDNF at synapses of mature hippocampal pyramidal cells reduce GABAergic transmission [331] [332] [333] [334] [335] by acting at postsynaptic TrkB receptors that act through protein kinase C and phosphatidylinositol 3-kinase-dependent signaling pathways and reduce the surface stability of GABA A Rs. 332, 335 Moreover, unlike in immature neurons, GABAergic input to adult neurons reduces the expression of BDNF. 336 The neural maturation deficit of dentate gyrus granule cells of BDNF-depleted mice 325 is reminiscent of similar cellular deficits in GABA A R g2 þ /À mice (see below). However, unlike the depressive-like phenotype of g2 þ /À mice detailed further below, mouse lines that are depleted in BDNF or TrkB, do not reliably show behavioral signs of depression, probably reflecting opposing functions of BDNF in the ventral tegmental area and nucleus accumbens vs hippocampus. 267 Moreover, AD-mediated increases in BDNF do not correlate with behavioral effects induced by BDNF administered to different brain regions. 337 Whereas BDNF deficits alone cannot explain the depressive-like phenotypes of GABA A Rdeficient mice, a hypomorphic human allele of BDNF (BDNF Val66Met ) is known to interact with environmental stress factors to increase the vulnerability for depression in people. [338] [339] [340] Preclinical experiments discussed further below suggest that these stress factors involve GABA A R deficits.
The anxiolytic effects of BZs remain intact even when hippocampal neurogenesis has been blocked. 266 This observation and the fact that BZs, unlike ADs, are effective as anxiolytics on acute treatment, indicate that the cellular substrate for anxiolytic effects of BZs is distinct from the one that mediates anxiolytic effects of ADs. Nevertheless, classical BZs are predicted to promote GABA/CREB/BDNF signaling and maturation of adult-born hippocampal neurons. However, drugs that potentiate the function of GABA A Rs do not only promote the maturation of immature neurons but they also seem to accelerate the cell-cycle exit of proliferating neural progenitor cells, which delimits the pool of replicating cells and negatively affects neurogenesis. 203, 284 These putative antagonistic effects of BZs on the total pool of immature dentate gyrus granule cells may explain the limited efficacy of BZs as antidepressants. GABA A R subtype-specific ligands that act selectively on certain GABA A R subtypes might circumvent this limitation. For example, the sedative hypnotic eszopiclone has BZ-like effects mainly on a2bg2 and a3bg2 subtypes of GABA A Rs 341 and promotes the survival of adult-born hippocampal granule cells in rats without affecting proliferation. 342, 343 In addition, eszopiclone has shown promise as a novel nonmonoaminergic antidepressant in patients. [190] [191] [192] 344 GABA A R-deficient mice as animal models of depression GABA A R g2 subunit-deficient mice and the function of postsynaptic subtypes of GABA A Rs GABAergic deficits cause depressive-like behavioral and cognitive deficits. The evidence for a role of GABAergic transmission summarized thus far does not prove a causal relationship between GABAergic deficits and depressive disorders. However, corresponding evidence is now available from mice engineered to model depressive disorders. In particular, mice rendered heterozygous for the g2 subunit (g2 þ /À ) of GABA A Rs have been characterized as an animal model of anxious depression that includes anxious-and depressive-like emotional behaviors in eight different tests 49, 110, 345 (for a summary of phenotypes, see Table 2 ). The g2 þ /À model is based on a modest functional deficit in postsynaptic GABA A Rs, as evidenced by unaltered GABA A R numbers but reduced punctate immunofluorescent staining representative of postsynaptic GABA A R subtypes and loss of GABA A R BZ-binding sites ranging from 6% (amygdala) to 35% (hippocampus) of GABA A Rs, depending on the brain region. 345 The magnitude of this deficit is comparable with GABA A R deficits observed in rodents that had been subjected to maternal deprivation stress, 108, 109 suggesting it is within the pathophysiological range triggered by adverse environments that are implicated in the etiology of mood disorders. The phenotype of g2 þ /À mice includes heightened neophobia and behavioral inhibition to naturally aversive situations, 345 reduced escape attempts under highly stressful conditions, 110 as well as anhedonia-like effects 49 that mimic core symptoms of anxious melancholic depression. Finally, g2 þ /À mice exhibit selective cognitive deficits such as an attentional bias for threat cues and impaired ambiguous cue discrimination, 345 which are reminiscent of cognitive impairments described in people at risk of or suffering from depression [348] [349] [350] [364] [365] [366] and principally attributed to the hippocampus 367 and the frontal and cingulate cortices. 368, 369 GABAergic deficits decrease the survival of adult-born hippocampal neurons. Consistent with the hypotheses that depressive disorders represent chronic deficits in neurotrophic support 370 and that GABAergic signaling has trophic function, 371 the g2 þ /À model shows normal proliferation of neural precursor cells but reduced survival of adult-born hippocampal granule cells. 110 The manifestation of this neurogenesis deficit in three different global and conditional g2-deficient mouse lines is correlated with the development of anxious depressive behavior, 110 suggesting that altered neurogenesis and behavioral phenotypes are causally linked.
GABAergic deficits cause HPA axis hyperactivity and increase responsiveness to ADs. The neuroendocrine phenotype of g2 þ /À mice includes constitutively elevated serum corticosterone and increased behavioral and endocrine sensitivity to treatment with ADs compared with wild-type mice, 49 which are known characteristics of severely depressed patients. 121, 352 Selective heterozygous inactivation of the g2 gene in the developing telencephalic forebrain (including the hippocampus and the frontal cortex, induced around embryonic day 10) is sufficient to induce HPA axis hyperactivity 49 and altered behavior, 110 indicating that the causative GABAergic deficit in these mice is extrahypothalamic (Figure 1 ). Glucocorticoids are known to reduce the expression of GABA A Rs in the forebrain, particularly in the frontal cortex and ventral hippocampus. 116, 125, 372 Moreover, recent evidence indicates that chronic but not acute stress results in the loss of parvalbuminpositive hippocampal interneurons. 124 Corresponding losses of interneurons in g2 þ /À mice might further enhance GABAergic deficits of g2 þ /À mice and amplify the observed defects in hippocampal neurogenesis. Defects in hippocampal neurogenesis in turn are sufficient to cause HPA axis hyperactivity. 126 Thus, GABA A R deficits in the telencephalon including the frontal cortex especially and the hippocampus may be both a cause for, and a consequence of, HPA axis hyperactivity, a feature that may initiate a self-perpetuating feedback loop that amplifies GABAergic deficits, with HPA axis hyperactivity serving as a critical link 49 ( Figure 1 ).
GABAergic deficits cause increased therapeutic efficacy of desipramine compared with fluoxetine. The selective norepinephrine reuptake inhibitor desipramine faithfully reverses both the By contrast, fluoxetine merely shows anxiolytic-like activity and fails to normalize depression-related behavior and HPA axis function of g2 þ /À mice. The qualitatively lesser response of g2 þ /À mice to fluoxetine than desipramine is reminiscent of severe subtypes of anxious depressive disorders, including melancholic depression, which tend to show greater responsiveness to TCAs than fluoxetine. [353] [354] [355] [356] [357] [358] [359] 373 Similar to the g2 þ /À model, clinical evidence indicates that elevated basal activity of the HPA axis is linked to poor responsiveness to fluoxetine in patients, 353, 360, 361 whereas normalization of HPA axis function by antidepressants is associated with remission from depression.
122,362
The g2 þ /À model shows selective vulnerability to mood disorders during early life. GABAergic transmission acts as a key regulator of brain development as indicated by its roles in neurogenesis, 204 290, 375, 376 To delineate the developmental time course and brain regions responsible for the anxious depressive phenotype of g2 þ /À mice, the behavioral and endocrine consequences of g2 subunit deficits were analyzed in two different conditional mutant strains (Cre-loxP system). 49, 110 Mice whose GABA A R deficit is initiated during embryogenesis but is limited to the telencephalon were found to replicate the behavioral phenotype and HPA axis hyperactivity of global KO mice, showing that HPA axis hyperactivity can develop independently of primary GABA A R deficits in the hypothalamus. 49 By contrast, delayed inactivation of the g2 gene during adolescence leads to developmentally delayed HPA axis hyperactivity, which is not accompanied by anxiety-or depression-related behaviors. 49, 110 These data suggest that the anxious depressivelike phenotype of g2 þ /À mice is caused by a developmental GABAergic deficit, the sequelae of which include inadequate neurotrophic support in the hippocampus and chronic HPA axis activation. This scenario is consistent with heightened vulnerability to anxiety and mood disorders in people during early life. [102] [103] [104] [105] [106] In summary, the GABA A R g2 þ /À mouse model includes behavioral, cognitive, cellular, neuroendocrine and developmental dimensions, as well as AD response characteristics expected of an animal model of melancholic depression and demonstrates that GABAergic deficits can be causative for all these phenotypes.
GABA A R d subunit-deficient mice and the function of extrasynaptic subtypes of GABA A Rs Pregnancy and parturition are associated with marked fluctuations in neuroactive steroids, which are linked to changes in mood and anxiety levels and are known to act mainly through d subunit-containing, nonsynaptic GABA A R subtypes. Failures of this neuroendocrine system to adapt to rapid changes in ovarian and adrenal hormone levels are implicated in postpartum depression and postpartum psychosis as evidenced by studies in rodents. Increased brain concentrations of neuroactive steroids during pregnancy of the rat are followed by a sudden decrease to control levels within 2 days of delivery 377 In the rat cortex, late-stage pregnancy shows decreased expression of the g2 and a5 subunits of GABA A Rs and a corresponding reduction in GABA A R function, which rebounds after delivery. 378 In dentate gyrus granule cells and CA1 pyramidal cells, the pregnancy of rats is associated with gradually increased and decreased expression of the d and g2 subunits of GABA A Rs, respectively, and this effect is normalized within 7 days of delivery. 170 Parturition is further associated with a rapid and transient increase in the expression of the a4 subunit in the same cells. 170 The change in GABA A R subunit composition during pregnancy is associated with increased tonic GABAergic inhibition compared with neurons analyzed during estrus and dependent on de novo neurosteroid synthesis. 170 Pregnancy in mice, unlike in rats, produces a significant downregulation of both the g2 and the d subunits and corresponding reductions in phasic and tonic GABAergic currents recorded from hippocampal granule cell neurons. 173 The reduced expression of GABA A Rs is believed to compensate for gonadal neurosteroid-mediated increases in GABA A R activity during pregnancy. Postpartum, the expression of GABA A R subunits and the phasic and tonic GABAergic currents recorded from granule cells rebound rapidly to levels found in virgin females. Interestingly, GABA A R d subunit KO mice, which are unable to adjust the expression of d-containing GABA A Rs show drastic deficits in GABAergic tonic inhibition specifically postpartum, which is associated with anxiety-and depression-related behavior, as well as abnormal maternal behavior. The pathology of d subunit KO mice thereby mirrors the symptoms of psychotic postpartum depression. 173 Dynamic changes in neurosteroid synthesis and GABA A R subunit expression also occur during the estrus cycle, and alterations in these mechanisms are implicated in the etiology of premenstrual dysphoric disorder. 172, 379 Elevated expression of a4bd receptors in late diestrus (high-progesterone phase) of the mouse causes increased tonic inhibition of dentate gyrus granule cells along with reduced anxiety. 172 The reduced expression of the d subunit during estrus is paralleled by upregulation of g2-containing GA-BA A Rs, which are comparatively insensitive to neurosteroids. Pharmacological blockade of neurosteroid synthesis from progesterone inhibits cyclic changes in GABA A R subunit expression and neural plasticity, whereas the progesterone receptor antagonist RU486 has no effect, indicating that neurosteroid synthesis rather than nuclear progesterone receptor activation underlies hormone-mediated neural plasticity. 117 Consistent with this interpretation, upregulation of GABA hypothesis of MDDs B Luscher et al a4bd receptors and tonic inhibition in hippocampal granule cells can be induced by treatment with THDOC or by acute stress, a condition known to increase neurosteroid levels. 117 Estrus cycle-associated changes in the expression of a4bd receptors have also been shown in the periaqueductal gray matter of female rats, 169 indicating that neurosteroidinduced plasticity is not limited to the dentate gyrus. In addition to the role of neurosteroids in regulating GABA A R subunit gene expression and as allosteric modulators of a4bd receptors, neurosteroids have been shown to regulate protein kinase C-mediated phosphorylation of GABA A Rs. 380 Protein kinase C is known to regulate the cell surface accumulation of GABA A Rs and GABAergic inhibition. 381 In summary, anomalous regulation of a4bd receptors by neurosteroids at the level of gene expression, channel gating and/or receptor trafficking is implicated in the etiology of postpartum depression and premenstrual dysphoric disorder.
Conclusions, limitations and outlook
The collective evidence summarized in this review indicates that reduced concentrations of GABA and altered expression of GABA A Rs are common abnormalities observed in MDDs. GABAergic transmission is vital for the control of stress and impaired by chronic stress, the most important vulnerability factor of MDD. Currently used antidepressants, which are designed to augment monoaminergic transmission, have in common that they ultimately serve to enhance GABAergic transmission. GABAergic excitation of immature neurons in the dentate gyrus has been identified as a key mechanism that provides trophic support and controls the dendritic maturation and survival of neurons, a process that serves as a molecular and cellular substrate of AD action. Finally, comparatively modest deficits in GABAergic transmission are sufficient to cause most of the cellular, behavioral, cognitive and pharmacological sequelae expected of an animal model of major depression. GABAergic transmission is further subjected to dynamic regulation by estrus-and pregnancy-associated changes in steroid hormone synthesis and altered expression of extrasynaptic GABA A Rs that may contribute preferentially to female-specific risk factors of mood disorders and explain the increased prevalence of MDD in the female population. The behavioral phenotypes of GABA A R g2 þ /À and d subunit KO mice suggest that deficits in both synaptic and nonsynaptic GABAergic transmission can contribute to depressive disorders.
Despite remarkable recent progress, we are left with a number of significant gaps in understanding. GABAergic deficits are not unique to MDD but are similarly implicated in a number of other neuropsychiatric disorders, especially schizophrenia. 382, 383 The question arises whether and how GABAergic deficits can help to differentiate between these different disorders. Moreover, the mechanisms that lead to initial GABAergic deficits remain poorly understood and they are so far not explained by mutations or functional polymorphisms in genes intimately involved in GABAergic transmission. We have listed a number of reasons that explain why currently available GABA-potentiating drugs are ineffective as antidepressants, yet it remains to be established whether next-generation GABAergic drugs that are more selective for GABA A Rs expressed in corticolimbic circuits affected in depression exhibit more convincing efficacy as antidepressants. Furthermore, a number of aspects of MDDs are not known to involve GABAergic deficits. For example, there is increasing preclinical evidence that resilience to stress and stress-induced neuropsychiatric disorders including depression is subject to epigenetic mechanisms, 384 yet there is little evidence for epigenetic regulation of GABAergic transmission. Transcriptional and immunohistochemical alterations in the brain of depressed patients suggest links between depressive disorders and inflammation, and apoptosis 385 and oligodendrocyte dysfunction, 81, 386 but none of these have been linked to GABAergic deficits. Future research should address these gaps in understanding and lead the path to improved antidepressant therapies that strive to correct the causal neurochemical imbalances rather than merely the symptoms of depression.
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